An established glaucoma patient with newly identified disease progression
It is critical to educate patients about the link between glaucoma and blindness, and to emphasize that, with proper treatment and regular follow-up visits, most glaucoma patients will not go blind. A combination of factors such as discussed in this interactive case involving a nonadherent patient who stopped taking the ocular hypotensive medications prescribed for her—personal problems, professional difficulties, and financial hardships—are all too frequent in the current economic climate.
Upon completion of this activity, participants should be able to analyze the efficacy, safety, and tolerability of current IOP-controlling agents, including prostaglandin analogues, which are commonly used in patients with glaucoma; develop strategies to better monitor patient adherence to prescribed treatment regimens for the management of glaucoma; and discuss common risk factors for the progression of glaucoma. » Go to this activity

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.